N@N

CBPO, BND, EUM, CPRX, SHY, MINT Are Seasonally Ripe To Go Down In the Next Five Weeks

January 27, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring the Seasonality of China Biologic Products, Inc. (NASDAQ:CBPO), Vanguard Total Bond Market ETF (NYSE:BND), ProShares Short MSCI Emerging Markets (NYSE:EUM), Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), iShares Barclays 1-3 Year Treasury Bond Fund (NYSE:SHY), PIMCO Enhanced Short Maturity Strategy Fund (NYSE:MINT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. buyins.net is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

The following stocks are expected to go Down:

  Symbol  Company                          Expected Return  Odds                 By The Following Date
  CBPO    China Biologic Products, Inc.    -2.26%           100.00% (8 of 8)     Monday, January 30th 2017
  BND     Vanguard Total Bond Market ETF   -0.89%           88.89% (8 of 9)      Tuesday, March 7th 2017
  EUM     ProShares Short MSCI Emerging Markets  -2.52%           88.89% (8 of 9)      Tuesday, February 14th 2017
  CPRX    Catalyst Pharmaceuticals Inc.    -6.31%           90.00% (9 of 10)     Friday, February 10th 2017
  SHY     iShares Barclays 1-3 Year Treasury Bond Fund  -0.16%           85.71% (12 of 14)    Tuesday, January 31st 2017
  MINT    PIMCO Enhanced Short Maturity Strategy Fund  -0.07%           100.00% (7 of 7)     Monday, January 30th 2017

China Biologic Products, Inc. (NASDAQ:CBPO) - China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People s Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing human hepatitis B immunoglobulin (pH4) for intravenous injection; human fibrinogen; immune globulin intravenous; human antithrombin III; human cytomegalovirus immunoglobulin; human coagulation factor IX; and human fibrin sealant products. The company sells its products directly, as well as through distributors. China Biologic Products, Inc. is headquartered in Beijing, the People s Republic of China..

Vanguard Total Bond Market ETF (NYSE:BND) - Vanguard Total Bond Market ETF.

ProShares Short MSCI Emerging Markets (NYSE:EUM) - M/L MAJ. 11INT MITTS.

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) - Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which completed Phase III clinical trial for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of MuSK-antibody positive myasthenia gravis. The company also develops CPP-115, a GABA aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy and other neurological indications, such as complex partial seizures and Tourette s disorder; and CPP-109 to treat Tourette s disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida..

iShares Barclays 1-3 Year Treasury Bond Fund (NYSE:SHY) - ISHARES LEHMAN 1-3YR.

PIMCO Enhanced Short Maturity Strategy Fund (NYSE:MINT) - MICRO-INTEGRATION CP.

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---